Lin BioScience, Inc. (TPEX:6696)

Market Cap	110.29B +352.7%
Revenue (ttm)	n/a
Net Income	-1.61B
EPS	-1.94
Shares Out	687.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,506,870
Open	159.00
Previous Close	156.50
Day's Range	156.00 - 161.50
52-Week Range	24.70 - 207.00
Beta	-0.25
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin t...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Zhengqi Wang
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6696

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error